Palmitoylethanolamide: A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold by Keppel Hesselink, J.M. et al.
Hindawi Publishing Corporation
International Journal of Inflammation
Volume 2013, Article ID 151028, 8 pages
http://dx.doi.org/10.1155/2013/151028
Review Article
Palmitoylethanolamide: A Natural Body-Own
Anti-Inflammatory Agent, Effective and Safe against
Influenza and Common Cold
J. M. Keppel Hesselink,1 Tineke de Boer,2 and Renger F. Witkamp3
1 Faculty of Medicine, University Witten/Herdecke, Alfred-Herrhausen-Straße 50, 58448 Witten, Germany
2Department of Research and Development, Institute for Neuropathic Pain, Spoorlaan 2a, 3735 MV Bosch en Duin, The Netherlands
3 Division of Human Nutrition (Bode 62), Wageningen University, P.O. Box 8129, 6700 EVWageningen, The Netherlands
Correspondence should be addressed to J. M. Keppel Hesselink; info@iocob.nl
Received 3 April 2013; Revised 9 June 2013; Accepted 10 June 2013
Academic Editor: Juan Carlos Kaski
Copyright © 2013 J. M. Keppel Hesselink et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Palmitoylethanolamide (PEA) is a food component known since 1957. PEA is synthesized and metabolized in animal cells via a
number of enzymes and exerts a multitude of physiological functions related to metabolic homeostasis. Research on PEA has been
conducted for more than 50 years, and over 350 papers are referenced in PubMed describing the physiological properties of this
endogenous modulator and its pharmacological and therapeutical profile. The major focus of PEA research, since the work of the
Nobel laureate Levi-Montalcini in 1993, has been neuropathic pain states and mast cell related disorders. However, it is less known
that 6 clinical trials in a total of nearly 4000 peoplewere performed and published last century, specifically studying PEA as a therapy
for influenza and the common cold. This was done before Levi-Montalcini’s clarification of PEA’s mechanism of action, analyzing
the role of PEA as an anti-inflammatory agent. We will review in depth these studies, as the results support the effectiveness and
safety of PEA in flu and respiratory infections.
1. Introduction
Palmitoylethanolamide (PEA) is a food component known
for more than 50 years. PEA is synthesized and metabolized
by different animal cell types and also present in plants.
It exerts a multitude of physiological functions related to
metabolic and cellular homeostasis. PEA was already iden-
tified in the 50s of the last century as a therapeutic substance
with potent anti-inflammatory properties. Since 1970, the
anti-inflammatory andother immune-modulating properties
of PEA have been shown in a number of placebo-controlled
double-blind clinical trials on influenza and common cold.
Positive results coincided with the clinical use of PEA in
former Czechoslovakia under the brand name Impulsin.
Since 2008, PEA has been marketed as a food for special
medical purposes in Italy and Spain, under the brand name
Normast (Epitech Srl). Recently, a food-supplement named
PeaPurewas introduced (JPRussell Science Ltd.). In theUSA,
PEA is under evaluation as a nutraceutical for inflammatory
bowel syndrome (proposed brand name Recoclix, CM&D
Pharma Ltd.; Nestle´).
Research on PEA has been conducted since its discovery
and over 350 papers are referenced in PubMed describing its
physiological properties and role as endogenous modulator
as well as its pharmacological and therapeutic effects. PEA is
an interesting anti-inflammatory therapeutic substance and
might also hold great promise for the treatment of a number
of (auto)immune disorders, including inflammatory bowel
disease and inflammatory diseases of the CNS. In this paper,
we will review the role of PEA as an anti-inflammatory agent
and as potential treatment for influenza and the common
cold. The main purpose is to highlight and discuss these
earliest findings, including the 6 double blind studies in these
indications published in the last century using Impulsin.
Although nearly forgotten, these findings could offer new
insights or perhaps even alternative options in the light of
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the intense debate around the efficacy and safety of the
oseltamivir and zanamivir In the present paper, we will
discuss the evolution of knowledge on the anti-inflammatory
activity of PEA and its effects in the treatment of respiratory
infections.
2. The Early Years: Anti-Inflammatory Activity
of Egg-Yolk Based on a Lipid-Fraction
The protective and anti-inflammatory effects of PEA can
be traced back in the literature to 1939 [1]. The American
bacteriologists Coburn andMoore demonstrated in that year
that feeding dried egg yolk to underprivileged children living
in poor parts of New York City prevented the recurrence
of rheumatic fever, in spite of repeated attacks of hemolytic
streptococcal infection.
After 1939, Coburn et al. studied 30 children at a con-
valescent rheumatic home and prescribed four egg yolks
daily. No other change in diet was made and no antibacterial
drugs were given. Twenty-two of these children contracted
24 serologically positive group-A streptococcal infections,
but none showed clinical evidence of rheumatic recurrences.
This was in sharp contrast to previous experience in the
convalescent home where rheumatic recurrences had been
frequently seen each year [2].
Subsequently in 1954, Coburn and colleagues were also
the first to report a phospholipid fraction prepared from egg
yolk that showed antiallergic activity in an assay in the guinea
pig [3].
The antiallergic factor of egg yolk was then purified by
Long and Martin in 1956 in such a way that it was clear
that this factor showed a biological and chemical similarity
to a preparation obtained earlier in 1950 from peanut and
what appeared to be a closely related substance described as
“vegetable lecithin” [4, 5].
The birth year of PEA was 1957. Kuehl Jr. and cowork-
ers reported to have succeeded in isolating a crystalline
anti-inflammatory factor from soybean lecithin and they
identified it as N-(2-hydroxyethyl)-palmitamide [6]. They
isolated the compound also from a phospholipid fraction
of egg yolk and from hexane-extracted peanut meal. The
product obtained was tested positively in a local passive
joint anaphylaxis assay in the guinea pig. When applying
their isolation procedure to soybean lecithin, they obtained
a partially purified fraction from which the homogeneous
factor was obtained by crystallization from cyclohexane. The
crystalline material had a melting point of 98-99∘C and was
described as neutral, optically inactive, and possessing the
chemical formula C18H37O2N.
Hydrolysis of the factor resulted in palmitic acid and
ethanolamine and thus the compound was identified as N-
(2-hydroxyethyl)-palmitamide. In order to close the circle of
isolation and identification, Kuehl et al. were able to synthe-
size the compound by reflux in ethanolamine with palmitic
acid according to a well-known procedure described in the
chemical literature of that time. Kuehl et al. further analyzed
the anti-inflammatory activity of a series of derivatives of
PEA and could prove that the basic moiety of the molecule
was responsible for its anti-inflammatory activity. The
nature of the acid group appeared to them to be of no
importance because in addition to ethanolamine itself,N-(2-
hydroxyethyl)-lauramide, S-(2-hydroxyethyl)-salicylamide,
and N-(2-hydroxyethyl)-acetamide all had potent anti-
inflammatory properties. These pharmacological properties
of the ethanolamine-derivatives appeared to be quite specific
since other homologs did not show a biological response in
the assay.
3. The Protective Effects of ‘‘Proto-PEA’’ in
Streptococcal Infections
Coburn was dedicated to find the cause and prevention of
rheumatic fever [7]. He presented his hypothesis that eggs
contained an important protective factor against infection,
especially in rheumatic fever, in 1960 in the Lancet [2]. He
argued that
(a) inadequate nutrition is part of a poor environment;
(b) rheumatic-fever children usually lack sufficient eggs
in their diets;
(c) the escape from poverty is followed by an increase
in the consumption of eggs and a decrease in the
incidence of rheumatic fever;
(d) supplementation of children’s diets with egg yolk or
certain fractions thereof is followed by decreased
rheumatic susceptibility; and
(e) there is a fraction of egg yolk, which in extremely
small amounts has been found to have high antialler-
gic activity in laboratory animals.
Coburn described his field studies in great detail [2].
Some of these findings are summarized below.
In Field study number 1, 𝑛 = 89, rheumatic boys and girls
living at home in New York City all received egg-enriched
food; no prophylactic drugs were given. Sixty children had
extra eggs during winter and spring months, and 29 served
as “controls.” Results were as follows: of the 29 children on
their normal diet (with many nutritional deficiencies) 11 had
a recurrence. Of the 35 children whose normal diet was
enriched with two eggs daily, a quart of milk, meat, butter,
and halibut-liver oil, 3 had a recurrence. Of the 25 children
whose normal diet was reinforced only with powdered egg
yolk (equivalent to six eggs daily), only 1 had a recurrence.
Field study number 2, 𝑛 = 56, was a two-year study
into the effect of giving egg-yolk powder (equivalent of four
egg yolks daily) to rheumatic children for three to four
weeks after they developed hemolytic (groupA) streptococcal
pharyngitis. No other treatment was given during this period.
Results were as follows: of 28 receiving the supplement,
only 1 showed fresh rheumatic activity, whereas among 28
“controls,” receiving no supplement, 10 children had fresh
rheumatic activity.
Field study number 3, 𝑛 = 40, was a one-year study
in which about 40 rheumatic children (with many dietary
deficiencies) received a daily supplement of only the protein
fraction from four egg yolks. Results were as follows: study
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was discontinued because of too many rheumatic recur-
rences.
Field study number 4, 𝑛 = 45, was a four-year study
(Chicago, period 1952–1956) in which a normal (nutritionally
deficient) diet of rheumatic children was reinforced with egg-
yolk alcohol-soluble material (A.S.M. fromWilson Laborato-
ries). No other changes in their inadequate diets were made;
no sulphonamides, antibiotics, or other significant drugs
were administered. Forty-five highly susceptible rheumatic
children received this supplement throughout the school year
from September to July. The equivalent of 3 egg yolks was
consumed, in the form of an elixir taken twice daily. All but
one of these rheumatic children was under fifteen years of
age. Results were as follows: a minimum of 17 attacks was
expected among them after streptococcal infections, but only
5 occurred.
Coburn concluded that “The data obtained under these
various conditions, both in New York and a decade later in
Chicago, were found to be statistically significant.” However,
he himself acknowledged that all studies had methodological
weaknesses [2].
Coburn discussed various experimental findings around
that time supporting the idea that there is at least one anti-
inflammatory substance present in egg-yolk alcohol-soluble
material, which was not present in the protein or acetone-
soluble material [5, 8]. The anti-inflammatory activity was
confirmed by different groups, for instance, by measuring
joint and skin lesions in either the Arthus or tuberculin
reaction. Various models were used and all results were
supportive of Coburn’s observations. The anti-inflammatory
compound clearly was part of the lipid fraction of the egg and
not the protein-water fraction.
4. Acceptance of PEA’s
Anti-Inflammatory Effects
Already in 1965 the anti-inflammatory activity of PEA
seemed to be quite well known in the scientific community.
Amongst others, Bachur, from the Laboratory of Clinical Bio-
chemistry and Experimental Therapeutics Branch, National
Heart Institute, National Institutes of Health, Bethesda, MD,
USA, and colleagues referred extensively to the findings of
Kuehl et al. (1957): “Kuehl et al. have previously reported the
isolation of PEA, as a naturally occurring anti-inflammatory
agent, from egg yolks. PEAwas known to occur in nature and
to have pharmacological activity” [9].
The group of Bachur analyzed the content of PEA and
found it to be present in several tissues of the rat and guinea
pig. The amounts found in liver were quite variable, but
PEA was consistently found in brain, liver, and muscle tissue
and was not detected in other tissues examined. Around
that time, the anti-inflammatory action of PEA could also
be demonstrated in a classical anti-inflammatory model, the
carrageen-induced edema model [10].
In the beginning of the 70s, the modifying effects of PEA
on immunological reactions were well established [11]. Perlik
et al. summarized [12] that “It has been shown that N-(2-
hydroxyethyl)-palmitamide (PEA) can decrease the intensity
of several inflammatory and immunological processes.”
However, between 1958 and 1969 the interest in this
compound had apparently decreased, as the same authors
stated that “Recently the interest on biological properties of
PEA has been revived because of its capacity to increase
nonspecific tolerance to several bacterial toxins.”
5. PEA: Anti-Influenza and Anticommon Cold
New interest arose by the end of the 60s, due to the fact
that SPOFA United Pharmaceutical Works brought PEA
on the market in 300mg tablets under the brand name
Impulsin to treat influenza and common cold. Different
clinical trials supported the effectiveness and safety of PEA
for this indication. Most probably the PEA in Impulsin was
not specifically formulated but details are not available.
In the period of 1969–1979, the results of a total of 5 trials
in adults and one trial in children were published. All of these
were double-blinded and placebo-controlled.
In the 1974 paper by Masek et al., the first two double-
blind controlled trials were described with a total of 1344
healthy subjects randomized (see Table 1: Masek 1972a and
Masek 1972b). There were in total 40 dropouts during the
studies, meaning that 1304 subjects completed the trials. The
goal of these two trials was to evaluate the prophylactic
and treatment efficacy of Impulsin in upper respiratory tract
infections. Both trials ended in February 1973 [13].
The first trial (Masek 1972a) was a treatment trial; 468
employees of the Skoda car factory were randomized in this
trial; of these 444 were completers, available for analysis. The
employees had to register the following symptoms: tempera-
ture of 37.5∘C or higher, headache, sore throat, myalgia, nasal
stuffiness or discharge, productive or dry cough, malaise, and
fatigue and had to make a clear impression of being sick.
Dosing was 600mg Impulsin three times daily during 12 days
(total daily dose 1800mg PEA).
The second trial was a prophylactic trial; 918 volunteers
between 18 and 20 years of age from an army unit were
included, and 899 completed the trial period. In this trial,
medical personnel registered the complaints during a period
of 8 weeks. The treatment schedule was 600mg PEA three
times daily for the first 3 weeks, after which a continuation
phase started based on a single dose of 600mg once daily for
6 weeks.
The results from the first trial showed that patients
receiving PEA had a lower number of episodes of fever,
headache, and sore throat, compared with placebo patients
(18 versus 33). PEA had less effect on symptoms such as nasal
stuffiness, discharge, and cough. The episodes of fever and
pain were significantly reduced by 45.5% in the PEA group
compared with the placebo group (𝑃 < 0.05). The beneficial
effect of PEA was apparent from the second week of the
trial. The total number of sickness days was also significantly
reduced in the PEA group. In the prophylactic trial, Masek
1972b, the incidence of disease in the PEA group was 40%
lower at week 6, and 32% lower at week 8 compared to placebo
(𝑃 < 0.0005).
In order to verify the conclusions, 3more trials in soldiers
were conducted. Soldiers were selected as they were housed
close together. In the period of 1973–1975, these new trials
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Table 1: Incidence of endpoints between both the PEA and the placebo groups.
Study (year) PEA (𝑛) Placebo (𝑛) % Protection Significance (𝑃)
Masek (1972a) [14] 223 221 45% <0.05
Masek (1972b) [14] 436 463 32% <0.0005
Kahlich (1973) [14] 436 465 34% <0.0002
Kahlich (1974) [14] 411 199 52% <0.002
Kahlich (1975) [14] 235 118 59% <0.004
Plesnik (1977) [15] 196 224 16% NS
were initiated (Kahlich 1973, 1974, and 1975 in Table 1) and
the results were reported in 1979 by Kahlich et al. [14]. Due to
the positive effects, it was felt to be unethical to randomize 1 : 1
and in the last two trials a different randomization schedule
was selected, in order to dose the majority of volunteers
with Impulsin (2 : 1). The authors compared the incidence of
clinical endpoints and the titers of influenza viruses between
both the PEA and placebo groups. In all three trials, the
soldiers in the PEAgrouphad significantly less symptoms and
were less often diagnosed as flu patients (see Table 1).
The evaluation of results according to morbidity, regard-
less of etiology, showed a significant reduction in acute
respiratory diseases (ARD) after administration of PEA. In
the 1973 trial (901 volunteers), 22.7% of ARD cases were
found in the PEA group compared to 34.4% in the placebo
group (𝑃 < 0.0002). The relevant values in the 1974 trial (610
volunteers) were 19.7% and 40.7% (𝑃 < 0.002) and in the 1975
trial (353 volunteers) 10.6% and 28.8% (𝑃 < 0.004) [14].
In all studies, Kahlich et al. studied serology in order to
document the influenza strains.The codes of these strains are
described below; however, the nomenclature is outdated. A
fourfold increase in the antibody titer was taken as evidence
for infection.
In the 1973 study, serum was obtained from 358 persons.
6.9% of the subjects experienced influenza A 2 E in the
PEA group and 18.7% of the subjects in the placebo group
(𝑃 < 0.005). The manifestation rate (MR), expressing the
proportion of sick persons out of all sensitive subjects with
serologically proved infection, was 15.4% in the PEA group
and 44.9% in the placebo group (𝑃 < 0.0002).
In the study of 1974, sera of 108 subjects were analyzed.
In the PEA group 3.8% of the subjects suffered from the
influenza B Hong-Kong and 21.4% of the subjects in the
placebo group (𝑃 < 0.01). The MR was 14.3% in the PEA
group and 57.1% in the placebo group (𝑃 < 0.001).
In the study of 1975, with serum gathered from 212
subjects, only 4.3% of the subjects in the PEA group had
influenza A Port Chalmers and 7% of the subjects in the
placebo group (nonsignificant difference).The incidence rate
of influenza A 2 England was 15.4% in the PEA group and
44.9% in the placebo group (𝑃 < 0.0002).
All these clinical trials pointed in the same direction
that PEA has clear treatment effects in respiratory infections,
can be used as influenza-prophylaxis, and is safe in its use.
Side effects were not reported, and Kahlich et al. explicitly
stated that “No side effects were registered after several
years of clinical testing of Impulsin in military and civilian
communities.” Kahlich et al. also pointed out that the effects
of PEA had a clear advantage over vaccines and antiviral
compounds such as amantadine, due to the optimal balance
of efficacy and side effects of PEA. They also stated that the
ease of application of PEAoffers the possibility to have a quick
therapeutic answer ready in case of a flu epidemic, especially
in cases of a mismatch between circulating strains and the
recommendations fromWHO.
A last placebo-controlled studywith PEA in children aged
11 to 15, examining the incidence of acute respiratory tract
infections, was performed in January 1976 [15]. 457 children
were included and divided into 2 groups; 64 children dropped
out. In the PEA group, 169 children completed the study who
received 300mgPEA 2 times daily with an interval of 6 hours.
The placebo group included 224 children receiving 2 placebo
tablets following the same regime as the PEA group.
Blood samples were taken before the study and 8 weeks
later in 65% of all children. After 8 weeks, children treated
with PEA had 15.7% fewer acute respiratory tract infections
than the control group. In children from 11 to 13 years
of age, the difference was even more pronounced: 25.5%.
Due to the short duration of the intake of PEA and the
absence of epidemic influenza during the trial period, the
differences between both groupswere not very large, and thus
no significance was reached.
Taken together, in the period between 1972 and 1977
in total 3627 patients and volunteers completed 6 different
placebo-controlled double-blind trials of which 1937 received
PEA up to 1800mg/day. Relevant side effects were not
reported and especially the trials conducted during the flu
season demonstrated a treatment, as well as a prophylactic
effect. The last study in children was not significant due to
the fact that during the study period no influenza epidemic
occurred.
6. PEA: Anti-Inflammatory Actions and
Its Mechanism of Action via PPAR-Alpha
Agonism and Other Targets
Since a decade, NAEs, both as saturated fatty amides (such
as PEA) and as poly-unsaturated forms, are found to play an
important physiological role in the modulation of immune
reactions in a number of autoimmune disorders via a number
of different receptors. For instance, Celiac disease is an
autoimmune disorder of the small intestine caused by a
reaction to gliadin, a gluten protein found in wheat. Most
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likely endocannabinoids play here an important modulating
role [16]. Anandamide and PEA concentrations in Celiac
disease were significantly elevated (100% and 90%, resp.)
during the active phase, as was the number of CB1 receptors.
The levels returned to normal after remission with a gluten-
free diet [17]. This clearly can be interpreted as the activation
of a self-repairing mechanism.
In an elegant study on the anti-inflammatory and pro-
apoptotic activities of anandamide, it was shown that it can
inhibit tumor necrosis factor-𝛼-induced NF-𝜅B activation
[18]. The NF-𝜅B inhibitory activity of anandamide was
independent of CB1 and CB2. Structure-activity relationships
demonstrated that analogs with saturated fatty acyl groups
were more active than unsaturated analogs. Saturated
acylethanolamides such as PEA therefore offer a new oppor-
tunity to modify chronic inflammation in autoimmune dis-
orders.
For a long period of time after the first description of
PEA, its mechanism of action remained unsolved, and this
led to a weaning interest in the compound after the set of
publications on the efficacy and safety of PEA in respiratory
infections and flu (in the period of 1970–1980). New interest
in the mechanism of action of PEA emerged only after the
work of the Nobel laureate Professor Rita Levi-Montalcini,
who published a seminal paper in 1993, opening the door
to a new understanding of PEA’s anti-inflammatory and
analgesic actions [19, 20]. Starting with her work, it became
clear that PEA regulates many pathophysiological processes,
and PEA has since been found to be effective in a number
of animal models for inflammation, neuroinflammation,
neurotoxicity, and chronic pain. Levi-Montalcini highlighted
the importance of activation of inflammatory cascades via
the activation of nonneuronal cells, such as the mast cells
[21]. PEA reduces mast cell migration and degranulation
and reduces the pathological overactivation of these cells
[21]. Mast cells shift from activated immune- to resting
phenotypes under influence of PEA. PEA further reduces the
activity of the proinflammatory enzymes, cyclooxygenase,
and endothelial, and inducible nitric oxide synthases. PEA
has an additional number of other pharmacological and
physiological properties, such as its affinity for the novel
orphan cannabinoid receptors GPR55 and GPR119 and for
the vanilloid receptor TRPV1, as well as for the nuclear
peroxisome proliferator-activated receptor-𝛼 (PPAR-𝛼) [22–
25]. These are probably the most relevant mechanisms of
action of PEA related to immunopathology.
7. Metabolism of PEA
7.1. Synthesis. In the body, PEA is synthesized from palmitic
acid (C16:0), which is the most common fatty acid in animals
and a product of normal fatty acid synthesis. Palmitic acid is
also present inmany foodstuffs including palm tree oil,meats,
cheeses, butter, and dairy products. Synthesis of PEA takes
place in membranes of various cell types and involves differ-
ent steps and partly parallel pathways.Themost studied path-
way goes viaN-palmitoyl-phosphatidyl-ethanolamine,which
belongs to the class of N-acylphosphatidylethanolamines
(NAPEs). NAPEs in general are present in phospholipid
membranes and function as stable precursors and source of
their respective NAEs. Palmitic acid is incorporated from
the sn-1 position of a donor phospholipid like phosphatidyl-
choline and transferred to an ethanolamine phospholipid, for
example, phosphatidylethanolamine, which is catalysed by a
Ca2+-dependent N-acyltransferase [26–28]. Next, free PEA
can be generated by a NAPE-hydrolyzing phospholipase D
(NAPE-PLD). However, recent studies also demonstrate the
presence of NAPE-PLD-independent multistep pathways to
form NAEs from NAPE [28].
An alternative pathway involves formation of NAEs from
N-acylated plasmalogen-type ethanolamine phospholipid
(N-acyl-plasmenylethanolamine) through both NAPE-PLD-
dependent and independent pathways [28]. In general, tissue
patterns ofNAEs are considered to reflect the local availability
of their precursor fatty acids in the phospholipidmembranes,
which are amongst others diet-related [29]. However, in case
of PEA, tissue levels hardly seem to be influenced by variation
in intake of dietary fatty acids, except in the small intestine
where dietary fat results in decreased levels of PEA and other
NAEs [27, 30]. Several studies indicate that free PEA levels
increase during inflammation [27, 30, 31]. Concentrations of
PEA in tissues and plasma have been published in various
papers, as recently reviewed by [27, 30, 31]. In humans, PEA
plasma concentrations are subject to considerable variation
during the day [32].
7.2. Breakdown. Like with other NEAs, endogenous PEA
is produced on demand and acts locally. Tissue levels are
tightly regulated through a balance between synthesis and
breakdown. The primary degrading enzyme is fatty acid
amide hydrolase (FAAH, now also known as FAAH-1),
localised on the endoplasmatic reticulum [33]. A second
FAAH enzyme, now called FAAH-2, was found in humans,
located on cytoplasmic lipid droplets [33, 34]. Recently,
a third NAE hydrolysing enzyme, N-acyl ethanolamine-
hydrolyzing acid amidase (NAAA) has been identified [28].
In the cytosol, fatty-acid binding proteins and heat-shock
proteins may serve as carriers for PEA to their degrading
enzymes [27].
8. PEA Anti-Influenza Activity: Decrease of
Proinflammatory Cytokines
After an infection with the influenza virus, the immune
system reacts by an increased production of many cytokine-
patterns. One pattern is related to a proinflammatory
response and a second one to an antiviral response. Infections
with virulent influenza viruses together with an aberrant and
excessive cytokine production are linked to increased mor-
bidity and mortality [35]. Increased production of specific
inflammatory cytokines, such as the tumor necrosis factor
(TNF)-𝛼, interleukin- (IL-) 1, IL-6, and IL-10, is characteristic
during an influenza infection [36]. More virulent viruses
are also associated with rapid and sustained induction of
inflammatory cytokines and such an early dysregulation of
the host response is seen as contributing to the severity and
outcome of the infection [37, 38]. The increased production
of proinflammatory cytokines, hypercytokinemia, is thus
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a clear player in the disease progression and death of patients
infected by influenza viruses [39, 40]. Recently, it was demon-
strated that highly elevated levels of serum IL-6 and IL-10
in A (H1N1) patients may also lead to disease progression
[41].
Overactive and nonfunctional hyper induction of proin-
flammatory cytokines might therefore play a key role in the
symptomatology and may lead to increased morbidity and
mortality. PEA is widely known for its anti-inflammatory
activity and to date more than 60 PubMed indexed papers
discuss this property of PEA. Its inhibitory action on TNF-
alpha secretion is sufficiently documented [42]. But PEA has
amuchwidermodulating effect on interleukins. For instance,
recently PEA was shown to significantly attenuate the
degree of intestinal injury and inflammation and to inhibit
proinflammatory cytokine production (TNF-𝛼, IL-1𝛽), adhe-
sion molecules (ICAM-1, P-selectin) expression, and NF-𝜅B
expression [43]. PEA also significantly decreases inflamma-
tion caused by ischemia-reperfusion injury, a pathological
state characterized by a strong enhanced interleukin-cascade
[44]. As PEA downmodulates a number of proinflammatory
cytokines, this could very well be the reason for the decreased
influenza and common cold symptomatology in individuals
treated with PEA.
9. Conclusions and Therapeutic Perspective
Over 350 papers have been referenced in PubMed in the
last 50 years describing the physiological properties of PEA
and its pharmacological and therapeutical profile. PEA has
a broad spectrum of biological targets and target molecules,
among which are PPAR-alpha, TRPV1, and orphan receptors
such as GPR-55.
This review on the role of PEA as an anti-inflammatory
agent and as a therapeutic agent for influenza and the
common cold discusses 6 clinical trials in a total of nearly
4000 patients and volunteers where PEA’s effectiveness and
safety for the treatment in these indications was shown.
Furthermore, since the focus on respiratory inflammation
and flu between 1971 and 1980, PEA has also been extensively
tested in a great variety of animal models for a number of
other indications, such as central and peripheral neuropathic
pain, pain in osteoarthritis, traumatic brain injury, multiple
sclerosis, amyotrophic lateral sclerosis, Alzheimer’s disease,
irritable bowel disease, interstitial cystitis, and other visceral
pain states. Consistently, the effective dose range has been
between 10 and 30mg PEA/kg bodyweight [45, 46]. Since the
work of Levi-Montalcini in the 90s of the twentieth century,
results of around 40 clinical trials in chronic pain have been
reported.However, themajority of these resultswere reported
in Italian and Spanish medical journals [37]. Since 2008, an
increasing number of clinical data have been reported in
English literature and results support its use in indications
such as sciatic pain and related neuropathic pain disorders.
As PEA clearly plays a fundamental role as a protective
and restorative modulating lipid precursor, its clinical role
is currently further evaluated in a variety of disorders such
as inflammatory bowel disorder, central neuropathic pain in
spinal cord disorders, various eye disorders such as glaucoma
and degenerative retina disorders, multiple sclerosis, amy-
otrophic lateral sclerosis, and Alzheimer’s disease.
Given the results of 6 clinical trials in flu and the common
cold, seen in the context of the serious criticism on the
efficacy and safety of oseltamivir and zanamivir, PEA should
be reconsidered by clinicians as a new treatment modality
for the flu and respiratory infections due to its documented
efficacy and more importantly its very benign side effect
profile. Furthermore, oseltamivir and zanamivir are known to
induce resistance; PEA has a very low likelihood of inducing
resistance due to its mechanism of action. Finally, the ease
of application of PEA offers the possibility to have a quick
therapeutic answer ready in case of a flu epidemic, especially
in cases of a mismatch between circulating strains and the
recommendations fromWHO.
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